Investor Presentaiton

BND-22 is an antagonist antibody that blocks ILT2, on innate and adaptive immune cells BND-22 enhances the ability of macrophages to phagocytose tumor cells BND-22 enhances anti-tumor activity of T cells and NK cells HLA-G "Don't Eat Me" Signal ILT2 Tumor Suppressed Macrophage BND-22 Tumor BND-22 ILT2 NK cells Inhibitory Signal CD8 T cells EMRA BND-22 HLA-G Activated Macrophage Inhibitory Signal ILT2 Tumor Suppressed Lymphocytes Tumor BND-22 BND-22 is a humanized IgG4 antibody that enhances the anti-tumor activity of immune cells by blocking ILT2 from binding to HLA-G and MHC-I TEMRA, effector memory T cells re-expressing CD45RA BIOND BIOLOGICS Biond Biologics Corporate Presentation | May 2021 | Non-confidential NK cells CD8 T cells EMRA Activated Lymphocytes 10

View entire presentation